SCHEMBL2444922

SCHEMBL2444922

Cc1cc(C2(c3ccc(Oc4ccc(N)cc4)c(C)c3)c3ccccc3-c3ccccc32)ccc1Oc1ccc(N)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.55
MAPT P10636 3/20 0.55
MEN1 O00255 3/20 0.55
KMT2A Q03164 3/20 0.55
KDM4E B2RXH2 1/20 0.55
LMNA P02545 1/20 0.55
OPRK1 P41145 1/20 0.55
ESR1 P03372 1/20 0.51
ESR2 Q92731 1/20 0.51
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
ALDH1A1 P00352 6/20 0.38
MAOA P21397 1/20 0.38
TEAD4 Q15561 1/20 0.37
POLB P06746 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MITF O75030 1/20 0.36
GAA P10253 1/20 0.36
GFER P55789 1/20 0.36
NLRP1 Q9C000 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29418322 0.92 SMN1; SMN2 (0.55) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL2447645 0.92 SMN1; SMN2 (0.55) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL2445179 0.89 MAPT (0.54) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL29418392 0.89 MAPT (0.54) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL5476258 0.87 ESR1 (0.49) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL2441859 0.87 ESR1 (0.49) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL2444966 0.86 ESR1 (0.48) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL2440305 0.85 MEN1 (0.50) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL2440430 0.84 ESR1 (0.44) SMN1; SMN2MAPTMEN1KMT2AKDM4E
SCHEMBL2444089 0.84 MEN1 (0.53) SMN1; SMN2MAPTMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2128193-B1 POROUS POLYIMIDE IBIDEN CO LTD (JP) 2013-06-19 EP disclosed
US-8022110-B2 Porous polyimide IBIDEN CO., LTD. (JP) 2011-09-20 US disclosed
US-20100048745-A1 POROUS POLYIMIDE IBIDEN CO., LTD (JP) 2010-02-25 US disclosed
EP-2128193-A1 POROUS POLYIMIDE Ibiden Co., Ltd. (JP) 2009-12-02 EP disclosed
US-20070255075-A1 Aromatic Diamine And Method For Manufacturing Same JFE CHEMICAL CORPORATION (JP) 2007-11-01 US disclosed
EP-1803705-A1 AROMATIC DIAMINE AND PROCESS FOR PRODUCING THE SAME JFE Chemical Corporation (JP) 2007-07-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070255075-A1 Aromatic Diamine And Method For Manufacturing Same AOC1, DDC, PADI1 SMN1; SMN2 2172/4885MAPT 1772/4885MEN1 2362/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.